Quantitative 68 Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177 Lu-PSMA-617 (VISION Trial)
Radiology · 01.08.2024 · 312 (2)
DOI: 10.1148/radiol.233460 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Radiology, erschienen am 01.08.2024. Verfasst von Phillip H Kuo und 22 weiteren Autor:innen. Beteiligte Einrichtung: From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); …. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Prostatic Neoplasms, Castration-Resistant, Positron Emission Tomography Computed Tomography, Lutetium. Die Arbeit wurde bisher 124-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Visual 68 Ga-PSMA-11 PET/CT eligibility criteria helped identify participants with metastatic castration-resistant prostate cancer who benefitted from 177 Lu-PSMA-617 therapy in the VISION trial, with higher 68 Ga-PSMA-11 uptake associated with improved outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Med…
ORCID-Profile: Michael J Morris, A Tuba Kendi, Kambiz Rahbar, Xiao X Wei, Johann de Bono, Bernd Krause, Oliver Sartor, Marcia Brackman, Andrew J Armstrong, Ken Herrmann
Förderung
- NCI NIH HHS
Zitieren
APA
Kuo, P. H., Morris, M. J., Hesterman, J., Kendi, A. T., Rahbar, K., Wei, X. X., Fang, B., Adra, N., Garje, R., Michalski, J. M., Chi, K., de Bono, J., Fizazi, K., Krause, B., Sartor, O., Tagawa, S. T., Ghebremariam, S., Brackman, M., Wong, C. C., …, & Herrmann, K. (2024). Quantitative 68 Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177 Lu-PSMA-617 (VISION Trial). Radiology, 312(2). https://doi.org/10.1148/radiol.233460
Vancouver
Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, et al. Quantitative 68 Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177 Lu-PSMA-617 (VISION Trial). Radiology. 2024;312(2). doi:10.1148/radiol.233460
BibTeX
@article{Kuo2024,
author = {Kuo, Phillip H and Morris, Michael J and Hesterman, Jacob and Kendi, A Tuba and Rahbar, Kambiz and Wei, Xiao X and Fang, Bruno and Adra, Nabil and Garje, Rohan and Michalski, Jeff M and Chi, Kim and de Bono, Johann and Fizazi, Karim and Krause, Bernd and Sartor, Oliver and Tagawa, Scott T and Ghebremariam, Samson and Brackman, Marcia and Wong, Connie C and Catafau, Ana M and Benson, Taylor and Armstrong, Andrew J and Herrmann, Ken},
title = {Quantitative 68 Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177 Lu-PSMA-617 (VISION Trial)},
journal = {Radiology},
year = {2024},
volume = {312},
number = {2},
doi = {10.1148/radiol.233460}
}
EUVIMED